Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

    NEXT STORY
    Beroni Group Announces Webcast from Biotech Showcase™ 2020 in San Francisco, USA
    PREV STORY
    Colorectal Cancer Therapeutics Market to reach USD 16.58 billion by 2026, Presence of Strong Oncology Portfolio to help Players Gain Competitive: Reports Fortune Business Insights™
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Athenex 將出席 2019年 ASCO 年度會議

    author_avatar
    NASDAQ Market News

    RedHill Biopharma to Present at the Jefferies 2016 London Healthcare Conference

    TEL-AVIV, Israel, Nov. 07, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” ...

    author_avatar
    NASDAQ Market News

    RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia®

    author_avatar
    NASDAQ Market News